2024
Immunosuppressive strategies in face and hand transplantation: a comprehensive systematic review of current therapy regimens and outcomes
Huelsboemer L, Boroumand S, Kochen A, Dony A, Moscarelli J, Hauc S, Stögner V, Formica R, Pomahac B, Kauke-Navarro M. Immunosuppressive strategies in face and hand transplantation: a comprehensive systematic review of current therapy regimens and outcomes. Frontiers In Transplantation 2024, 3: 1366243. PMID: 38993787, PMCID: PMC11235358, DOI: 10.3389/frtra.2024.1366243.Peer-Reviewed Original ResearchCMV infectionImmunosuppressive regimensImmunosuppressive strategiesTransplant recipientsIncidence of rejection episodesClinical CMV infectionTriple maintenance therapyIncidence of rejectionEpisodes of rejectionIndividualized immunosuppressive regimensEffective immunosuppressive therapySystematic reviewFace transplant patientsHand transplant recipientsHand transplantationFacial graftImmunosuppressive therapyMaintenance therapyRejection episodesFacial mucosaGraft lossGraft rejectionTherapy regimensTransplant patientsRenal failure
2023
Randomized Trial of Hyperimmune Globulin for Congenital CMV Infection — 2-Year Outcomes
Hughes B, Clifton R, Rouse D, Saade G, Dinsmoor M, Reddy U, Pass R, Allard D, Mallett G, MacPherson C, Wapner R, Metz T, Goodnight W, Tita A, Costantine M, Swamy G, Heyborne K, Chien E, Chauhan S, El-Sayed Y, Casey B, Parry S, Simhan H, Napolitano P, Macones G. Randomized Trial of Hyperimmune Globulin for Congenital CMV Infection — 2-Year Outcomes. New England Journal Of Medicine 2023, 389: 1822-1824. PMID: 37937785, PMCID: PMC10683876, DOI: 10.1056/nejmc2308286.Peer-Reviewed Original ResearchMulticenter study of universal prophylaxis versus pre‐emptive therapy for patients at intermediate risk (R+) for CMV following heart transplantation
Lerman J, Green C, Molina M, Maharaj V, Ortega‐Legaspi J, Sen S, Flattery M, Maziarz E, Shah K, Martin C, Alexy T, Shah P, Morris A, DeVore A, Cole R. Multicenter study of universal prophylaxis versus pre‐emptive therapy for patients at intermediate risk (R+) for CMV following heart transplantation. Clinical Transplantation 2023, 37: e15065. PMID: 37392192, PMCID: PMC10592402, DOI: 10.1111/ctr.15065.Peer-Reviewed Original ResearchConceptsAcute cellular rejectionCardiac allograft vasculopathyUniversal prophylaxisPreemptive therapyHeart transplantHT recipientsGrade 2RIntermediate riskCMV-related complicationsIncidence of leukopeniaPre-emptive therapyAnti-CMV therapyEnd-organ diseaseInitiation/escalationAllograft vasculopathyCellular rejectionCMV DNAemiaCMV preventionGraft outcomeHeart transplantationCMV infectionSecondary outcomesPrimary outcomeProphylaxis strategiesSuch patients
2022
Cytomegalovirus-related Complications and Management in Facial Vascularized Composite Allotransplantation: An International Multicenter Retrospective Cohort Study
Kauke-Navarro M, Panayi AC, Formica R, Marty F, Parikh N, Foroutanjazi S, Safi AF, Mardini S, Razonable RR, Morelon E, Gelb B, Rodriguez E, Lassus P, Pomahac B. Cytomegalovirus-related Complications and Management in Facial Vascularized Composite Allotransplantation: An International Multicenter Retrospective Cohort Study. Transplantation 2022, 106: 2031-2043. PMID: 35389381, DOI: 10.1097/tp.0000000000004132.Peer-Reviewed Original ResearchConceptsRetrospective cohort studyAntiviral prophylaxisCohort studyComposite allotransplantationInternational multicenter retrospective cohort studyMulticenter retrospective cohort studyCMV-related complicationsFirst year posttransplantHigh-risk transplantsMore rejection episodesHigh-risk groupFacial Vascularized Composite AllotransplantationAllograft-related complicationsVascularized Composite AllotransplantationPaucity of dataAllograft lossCMV diseaseCMV viremiaCytomegalovirus serostatusR serostatusRejection episodesCMV infectionPrompt treatmentActive surveillancePatientsCytomegalovirus infections in infants in Uganda: Newborn-mother pairs, neonates with sepsis, and infants with hydrocephalus
Hehnly C, Ssentongo P, Bebell L, Burgoine K, Bazira J, Fronterre C, Kumbakumba E, Mulondo R, Mbabazi-Kabachelor E, Morton S, Ngonzi J, Ochora M, Olupot-Olupot P, Mugamba J, Onen J, Roberts D, Sheldon K, Sinnar S, Smith J, Ssenyonga P, Kiwanuka J, Paulson J, Meier F, Ericson J, Broach J, Schiff S. Cytomegalovirus infections in infants in Uganda: Newborn-mother pairs, neonates with sepsis, and infants with hydrocephalus. International Journal Of Infectious Diseases 2022, 118: 24-33. PMID: 35150915, PMCID: PMC9058984, DOI: 10.1016/j.ijid.2022.02.005.Peer-Reviewed Original ResearchConceptsNewborn-mother pairsCMV prevalenceClinical sepsisCytomegalovirus infectionCerebrospinal fluidPrevalence of CMVQuantitative PCRCMV positivityPostinfectious hydrocephalusVaginal sheddingCMV infectionHIV seropositivityNeonatal ageMaternal ageMaternal vaginalRisk factorsMedical CenterLong-term consequencesMother pairsSepsisNeonatesInfantsPrevalenceHydrocephalusCMVA Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection
Hughes B, Clifton R, Rouse D, Saade G, Dinsmoor M, Reddy U, Pass R, Allard D, Mallett G, Fette L, Gyamfi-Bannerman C, Varner M, Goodnight W, Tita A, Costantine M, Swamy G, Gibbs R, Chien E, Chauhan S, El-Sayed Y, Casey B, Parry S, Simhan H, Napolitano P, Macones G. A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection. Obstetrical & Gynecological Survey 2022, 77: 16-18. DOI: 10.1097/01.ogx.0000805168.83387.d5.Peer-Reviewed Original Research
2020
Prenatal Treatment of Congenital Cytomegalovirus With Valganciclovir: A Case Report
DeNoble AE, Saccoccio FM, Permar SR, Hughes BL. Prenatal Treatment of Congenital Cytomegalovirus With Valganciclovir: A Case Report. Clinical Infectious Diseases 2020, 71: 2506-2508. PMID: 32198512, DOI: 10.1093/cid/ciaa305.Peer-Reviewed Original ResearchConceptsCommon congenital infectionCongenital CMV infectionCases of hydropsCongenital cytomegalovirusCongenital infectionCMV infectionNeonatal treatmentNeurologic injuryCCMV infectionInfectious causesCase reportFetal anomaliesPrenatal treatmentTreatment strategiesMinimal sequelaeCytomegalovirusInfectionValganciclovirTreatmentSequelaeHydropsPregnancyInjury
2019
Association between lymphocyte subsets and cytomegalovirus infection status among patients with systemic lupus erythematosus
Qin L, Qiu Z, Hsieh E, Geng T, Zhao J, Zeng X, Wan L, Xie J, Ramendra R, Routy JP, Li T. Association between lymphocyte subsets and cytomegalovirus infection status among patients with systemic lupus erythematosus. Medicine 2019, 98: e16997. PMID: 31574798, PMCID: PMC6775378, DOI: 10.1097/md.0000000000016997.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusCMV diseaseLymphocyte subsetsCMV viremiaT cellsSLE patientsCMV infectionInfection statusLupus erythematosusNatural killer cell countsMultivariable logistic regression analysisCMV infection statusCytomegalovirus infection statusEvidence of CMVHospitalized SLE patientsLymphocyte subset countsDifferent lymphocyte subsetsCMV-infected patientsT-cell lymphopeniaLogistic regression analysisTotal lymphocytesUninfected patientsClinical characteristicsSubset countsMultivariable analysis
2017
Valnoctamide Inhibits Cytomegalovirus Infection in Developing Brain and Attenuates Neurobehavioral Dysfunctions and Brain Abnormalities
Ornaghi S, Hsieh LS, Bordey A, Vergani P, Paidas MJ, van den Pol AN. Valnoctamide Inhibits Cytomegalovirus Infection in Developing Brain and Attenuates Neurobehavioral Dysfunctions and Brain Abnormalities. Journal Of Neuroscience 2017, 37: 6877-6893. PMID: 28630251, PMCID: PMC5518418, DOI: 10.1523/jneurosci.0970-17.2017.Peer-Reviewed Original ResearchConceptsAnti-CMV drugsBrain defectsNeurological outcomeCMV replicationMouse brainAvailable anti-CMV drugsHuman fetal brain cellsLong-term neurological outcomeTreatment of cytomegalovirusAdverse neurological outcomesUninfected control miceCommon infectious causeLong-term motorSecond trimester human fetusesUninfected control animalsFetal brain cellsHuman fetal astrocytesJuvenile male miceWeeks of lifeAdverse side effectsEfficacious therapeutic effectsDetectable adverse effectsNewborn mouse brainLevels of virusCMV infectionPhase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients
Ishida JH, Patel A, Mehta AK, Gatault P, McBride JM, Burgess T, Derby MA, Snydman DR, Emu B, Feierbach B, Fouts AE, Maia M, Deng R, Rosenberger CM, Gennaro LA, Striano NS, Liao XC, Tavel JA. Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients. Antimicrobial Agents And Chemotherapy 2017, 61: 10.1128/aac.01794-16. PMID: 27872061, PMCID: PMC5278717, DOI: 10.1128/aac.01794-16.Peer-Reviewed Original ResearchConceptsHigh-risk kidney transplant recipientsKidney transplant recipientsCMV viremiaTransplant recipientsCMV diseaseCMV infectionCytomegalovirus infectionMonoclonal antibodiesCMV-seronegative recipientsCMV-seropositive donorsLess CMV diseasePlacebo-controlled trialTime of transplantKidney transplantationPlacebo groupAdverse eventsKidney transplantMedian timeSignificant complicationsPlaceboTreatment groupsPatientsViremiaInfectionWeeks
2016
In utero cytomegalovirus infection and development of childhood acute lymphoblastic leukemia
Francis SS, Wallace AD, Wendt GA, Li L, Liu F, Riley LW, Kogan S, Walsh KM, de Smith AJ, Dahl GV, Ma X, Delwart E, Metayer C, Wiemels JL. In utero cytomegalovirus infection and development of childhood acute lymphoblastic leukemia. Blood 2016, 129: 1680-1684. PMID: 27979823, PMCID: PMC5364339, DOI: 10.1182/blood-2016-07-723148.Peer-Reviewed Original ResearchConceptsAcute lymphoblastic leukemiaCMV infectionCytomegalovirus infectionLymphoblastic leukemiaChildhood acute lymphoblastic leukemiaUtero cytomegalovirus infectionCongenital CMV infectionCommon childhood cancerActive viral transcriptionBone marrow specimensNon-Hispanic whitesTiming of infectionNewborn blood samplesEtiologic roleRisk factorsChildhood cancerHealthy controlsHigh prevalenceMarrow specimensLeukemia blastsBlood samplesPrenatal originEtiologic agentInfectionHispanic childrenCMV Viremia and African-American Ethnicity Are Risk Factors for Post-Engraftment Blood Stream Infections in Pediatric Allogeneic Blood and Marrow Transplantation
Sano H, Hilinski J, Applegate K, Camacho-Gonzalez A, Chandrakasan S, Chiang K, Haight A, Krishnamurti L, Stenger E, Qayed M, Horan J. CMV Viremia and African-American Ethnicity Are Risk Factors for Post-Engraftment Blood Stream Infections in Pediatric Allogeneic Blood and Marrow Transplantation. Blood 2016, 128: 3397. DOI: 10.1182/blood.v128.22.3397.3397.Peer-Reviewed Original ResearchBlood stream infectionsAfrican American ethnicityCMV viremiaAllogeneic BMTAllogeneic bloodMarrow transplantationRisk factorsMultivariate analysisGrade III/IVAllogeneic BMT patientsAlternative donor transplantsFrequency of neutropeniaPost-engraftment periodPre-emptive therapyTransplant related mortalityGram-positive cocciAcute GVHDBMT patientsCytomegalovirus viremiaEngrafted patientsUnrelated cordsUnrelated marrowClinical characteristicsCMV infectionCumulative incidenceGuillain–Barré syndrome associated with resistant cytomegalovirus infection after face transplantation
Alhefzi M, Aycart M, Bueno E, Kueckelhaus M, Fischer S, Snook R, Sharfuddin A, Hadad I, Malla P, Amato A, Pomahac B, Marty F. Guillain–Barré syndrome associated with resistant cytomegalovirus infection after face transplantation. Transplant Infectious Disease 2016, 18: 288-292. PMID: 26910286, DOI: 10.1111/tid.12516.Peer-Reviewed Original ResearchConceptsGuillain-Barré syndromeLower extremity paresthesiasResistant cytomegalovirus infectionLower extremity weaknessSensorimotor axonal polyneuropathyExtremity weaknessIntravenous immunoglobulinAxonal polyneuropathyCMV infectionCytomegalovirus infectionExtremity paresthesiasImmune controlAxonal formTransplantationFacial allograftFace transplantationElectrophysiological evidenceMonthsSyndromeInfectionParesthesiaPolyneuropathyAllograftsRecurrenceCMV
2015
Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination
Makhani N, Banwell B, Tellier R, Yea C, McGovern S, O’Mahony J, Ahorro JM, Arnold D, Sadovnick AD, Marrie RA, Bar-Or A, Network O. Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination. Multiple Sclerosis Journal 2015, 22: 385-388. PMID: 26199356, DOI: 10.1177/1352458515595876.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, ViralChickenpoxChildCohort StudiesCytomegalovirus InfectionsDemyelinating DiseasesEnzyme-Linked Immunosorbent AssayEpstein-Barr Virus InfectionsFemaleHerpes SimplexHumansImmunoglobulin GMaleMultiple SclerosisProportional Hazards ModelsProspective StudiesSeroepidemiologic StudiesConceptsCMV infectionEpstein-Barr virus infectionRemote EBV infectionSubsequent MS diagnosisImportant prognostic informationMultiple sclerosis riskVaricella-zoster virusHerpes simplex virusCMV seroprevalenceDemyelinating syndromesMonophasic ADSEBV infectionCytomegalovirus infectionProspective cohortMS diagnosisViral exposurePrognostic informationMS outcomesVirus infectionHigh riskSimplex virusMS developmentInfectionProtective factorsChildren
2014
Splenic rupture associated with primary CMV infection, AMSAN, and IVIG
de Havenon A, Davis G, Hoesch R. Splenic rupture associated with primary CMV infection, AMSAN, and IVIG. Journal Of Neuroimmunology 2014, 272: 103-105. PMID: 24856574, DOI: 10.1016/j.jneuroim.2014.05.004.Peer-Reviewed Original ResearchConceptsPrimary cytomegalovirus infectionGuillain-Barré syndromeIntravenous immunoglobulinSplenic ruptureCytomegalovirus infectionPrimary CMV infectionTwo-hit scenarioSequestration of erythrocytesExtravascular hemolytic anemiaRisk of ruptureCMV infectionRare complicationHemolytic anemiaImmunoglobulinInfectionSyndromeRuptureTreatmentRiskIVIGAMSANComplicationsPatientsAnemiaSpleen
2013
Cytomegalovirus Glomerulopathy and Cytomegalovirus Interstitial Nephritis on Sequential Transplant Kidney Biopsies
Vichot AA, Formica RN, Moeckel GW. Cytomegalovirus Glomerulopathy and Cytomegalovirus Interstitial Nephritis on Sequential Transplant Kidney Biopsies. American Journal Of Kidney Diseases 2013, 63: 536-539. PMID: 24568687, PMCID: PMC7210789, DOI: 10.1053/j.ajkd.2013.08.021.Peer-Reviewed Original ResearchConceptsSecond biopsy specimenBiopsy specimenCMV infectionInterstitial nephritisKidney biopsyKidney transplant biopsy specimensEndothelial cellsCMV-negative patientsCMV-positive cellsCMV-positive donorsFirst biopsy specimenKidney transplant graftsSequential kidney biopsiesTransplant biopsy specimensTransplant kidney biopsiesGlomerular capillary endothelial cellsTubular epithelial cellsGlomerular capillary loopsGlomerular capillary luminaCapillary endothelial cellsCytoplasmic viral particlesKidney transplantTubular injuryLymphoplasmacytic infiltrateTransplant grafts
2012
The Relationship of Cytomegalovirus (CMV) Infection with circulatory IFN-α levels and IL-7 receptor α expression on CD8+ T cells in Human Aging (105.16)
Lee N, Lee W, Shin M, Kang Y, Jeon S, Kang I. The Relationship of Cytomegalovirus (CMV) Infection with circulatory IFN-α levels and IL-7 receptor α expression on CD8+ T cells in Human Aging (105.16). The Journal Of Immunology 2012, 188: 105.16-105.16. DOI: 10.4049/jimmunol.188.supp.105.16.Peer-Reviewed Original ResearchEM CD8IFN-α levelsT cellsCMV infectionCytomegalovirus infectionIL-7 Receptor α ExpressionHuman effector memory CD8IL-7 receptor alphaCMV immune statusEffector memory CD8Elderly peopleT cell subsetsReceptor α expressionT cell homeostasisAge-associated expansionHigh-affinity receptorCytokine levelsMemory CD8Naïve CD8Cell subsetsImmune statusPlasma levelsCD8IL-7Α expression
2011
Studying the mechanisms for increased IL-7Rαlow Memory CD8+T cells in the elderly (150.11)
Shin M, Lee W, Lee J, Kim S, Lee N, Kang I. Studying the mechanisms for increased IL-7Rαlow Memory CD8+T cells in the elderly (150.11). The Journal Of Immunology 2011, 186: 150.11-150.11. DOI: 10.4049/jimmunol.186.supp.150.11.Peer-Reviewed Original ResearchMemory CD8T cellsAge-associated expansionYoung donorsCMV infectionIL-15Elderly donorsIL-15-mediated proliferationT cell receptor repertoireTCR-mediated proliferationIL-15 expressionCell receptor repertoireCell subsetsCD8Better survivalReceptor repertoireCMVElderly peoplePotential roleSignificant differencesIndependent mechanismsInfectionProliferationSurvivalCellsA Case of Cytomegalovirus Colitis in Chronic Adult T-Cell Leukemia/Lymphoma
Park H, Kim D, Kim J, Kim Y, Cho M, Ok T, Jang S, Lee K. A Case of Cytomegalovirus Colitis in Chronic Adult T-Cell Leukemia/Lymphoma. Journal Of Yeungnam Medical Science 2011, 28: 187-191. DOI: 10.12701/yujm.2011.28.2.187.Peer-Reviewed Original ResearchAdult T-cell leukemia/lymphomaChronic adult T-cell leukemia/lymphomaT-cell leukemia/lymphomaLeukemia/lymphomaAcute-type adult T-cell leukemia/lymphomaHuman T-cell lymphotrophic virus type ILymphotrophic virus type ISymptoms of feverMature T cellsVirus type ICMV colitisCytomegalovirus colitisCMV infectionCytomegalovirus infectionOpportunistic infectionsT cellsLow prevalenceInfectionColitisLymphomaType IPatientsDiarrheaFeverMalignancy
2010
Thrombosis associated with acute cytomegalovirus infection: A meta-analysis
Justo D, Finn T, Atzmony L, Guy N, Steinvil A. Thrombosis associated with acute cytomegalovirus infection: A meta-analysis. European Journal Of Internal Medicine 2010, 22: 195-199. PMID: 21402253, DOI: 10.1016/j.ejim.2010.11.006.Peer-Reviewed Original ResearchConceptsAcute CMV infectionSplanchnic vein thrombosisCMV infectionImmunocompetent patientsImmunocompromised patientsVein thrombosisTreated with antiviral agentsDuration of anticoagulant therapyClinical characteristics of patientsIn-hospital mortality rateSigns of thrombosisIncidence of thrombosisCharacteristics of patientsAcute cytomegalovirusAnticoagulant therapyFemale-male ratioClinical characteristicsSplenic infarctionInherited predispositionHospitalized patientsThrombosisPatientsAntiviral agentsMedical literatureClinical experience
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply